Vitamin B12 deficiency anemia is a form of megaloblastic anemia characterized by impaired DNA synthesis in erythroid precursors. Vitamin B12, or cobalamin, is an essential cofactor for metabolic reactions fundamental to proper cellular development, particularly in rapidly proliferating hematopoietic cells. When its intake or utilization is insufficient, bone marrow erythroid precursors fail to complete the replicative cycle properly, arrest their maturation, and undergo early intramedullary death. This mechanism results in ineffective erythropoiesis, where the bone marrow, although hyperplastic, is unable to produce functional red blood cells, leading to anemia characterized by large (macrocytic) and fragile (megaloblastic) cells.
Beyond the hematological damage, vitamin B12 deficiency causes profound neurological and gastrointestinal alterations. Impaired myelin synthesis and abnormal metabolism of odd-chain fatty acids lead to progressive dysfunction of peripheral and central nerve pathways. If not promptly recognized, vitamin B12 deficiency anemia can evolve into permanent neurological damage.
The prevalence of vitamin B12 deficiency increases with age and with predisposing conditions such as autoimmune diseases, gastrointestinal disorders, diets low in animal-derived foods, alcoholism, and surgical interventions on the stomach or ileum.
The correct availability of vitamin B12 in the body requires a complex sequence of steps, each of which can be interrupted by specific diseases or clinical conditions. Deficiency can therefore result from alterations in intake, release, binding, absorption, transport, or intracellular utilization of cobalamin.
Vitamin B12 is found exclusively in animal-derived foods such as meat, fish, eggs, and dairy products. In cases of strict vegan diets without adequate supplementation, or in severe malnutrition, cobalamin intake may be insufficient. Chronic alcoholism also represents an aggravating factor, both due to reduced dietary intake and direct damage to the gastrointestinal mucosa impairing absorption.
Once ingested, vitamin B12 is bound to dietary proteins. In the stomach, the acidic environment allows hydrochloric acid and pepsin to release cobalamin, making it available for subsequent binding to salivary R-protein. Any condition that reduces gastric acidity (such as autoimmune atrophic gastritis, gastrectomy, chronic use of antacids or proton pump inhibitors) impairs this release, making dietary vitamin B12 inaccessible.
After being freed, vitamin B12 initially binds to R-protein. In the duodenum, thanks to pancreatic proteases, it is released from R-protein and binds to the intrinsic factor (IF), a glycoprotein secreted by gastric parietal cells. This bond is essential for subsequent intestinal absorption. In pernicious anemia, an autoimmune disease, antibodies develop against intrinsic factor or parietal cells, preventing the formation of the vitamin B12–IF complex and thus impairing absorption, even with normal dietary intake.
The vitamin B12–intrinsic factor complex reaches the terminal ileum, where it is absorbed through specific receptors located on the ileal mucosa. Diseases damaging the ileum, such as Crohn's disease, surgical ileal resections, or celiac disease, reduce the efficiency of this process. Parasitic infections, such as infestation by Diphyllobothrium latum (fish tapeworm), can also compete for vitamin B12, depriving the host organism.
Once absorbed, vitamin B12 binds to transcobalamin II for plasma transport and delivery to tissues. Rare genetic defects in transcobalamin or transport proteins can cause a functional deficiency, even with normal serum vitamin B12 levels. Inside cells, vitamin B12 is converted into its active forms necessary for metabolic reactions.
Vitamin B12 is involved in two key enzymatic reactions. The first is the conversion of homocysteine to methionine, mediated by methionine synthase, providing methyl groups indispensable for DNA synthesis. The second is the conversion of methylmalonyl-CoA to succinyl-CoA, catalyzed by methylmalonyl-CoA mutase, essential for fatty acid metabolism and myelin formation.
Vitamin B12 deficiency compromises DNA synthesis in erythroid precursors, causing a maturation arrest in the S phase of the cell cycle. Cells attempt replication, but nuclear division is defective while cytoplasmic growth continues, resulting in the formation of megaloblasts with immature nuclei and hypertrophic cytoplasm. Most of these precursors undergo intramedullary apoptosis, causing ineffective erythropoiesis and reduced production of mature red blood cells, leading to anemia.
At the same time, accumulation of methylmalonyl-CoA and reduced methionine synthesis impair myelin metabolism, causing neurological damage affecting the posterior and lateral columns of the spinal cord, nerve roots, and peripheral pathways.
The onset of anemia due to vitamin B12 deficiency is favored by a series of conditions that interfere with the intake, absorption, or utilization of the vitamin. The main risk factors are related to both dietary situations and organic diseases impairing various stages of cobalamin metabolism.
Strict vegan diets, devoid of animal-derived foods, are a primary cause of reduced dietary intake. Without adequate supplementation, hepatic stores of vitamin B12 can be depleted within a few years, leading to clinically manifest deficiencies. Similarly, non-strict vegetarianism may represent a risk, especially in elderly individuals or children.
Gastrointestinal diseases play a central role. Autoimmune atrophic gastritis, characterized by the destruction of gastric parietal cells, reduces both hydrochloric acid and intrinsic factor production, impairing the release and absorption of the vitamin. Other diseases, such as Crohn's disease, celiac disease, and surgical resections of the terminal ileum, directly compromise the ileal absorption phase of vitamin B12.
The chronic use of certain medications can further predispose to deficiency. Proton pump inhibitors and H2 antagonists alter gastric pH, hindering the release of vitamin B12 from protein complexes. Metformin, widely used in type 2 diabetes, is associated with a reduction in intestinal cobalamin absorption.
Finally, chronic alcoholism acts at multiple levels, reducing dietary intake, damaging the intestinal mucosa, and interfering with the processes of absorption and utilization of the vitamin.
Prevention is based on the early identification of at-risk individuals and the adoption of targeted corrective measures:
The early diagnosis of subclinical deficiency allows for the prevention of overt anemia and, more importantly, the avoidance of irreversible neurological damage associated with prolonged deficiency.
The symptomatology of anemia due to vitamin B12 deficiency is broad and complex, as the vitamin deficit simultaneously affects the hematopoietic system, the nervous system, and, to a lesser extent, the gastrointestinal tract. The signs and symptoms vary according to the duration of the deficiency, its severity, and the individual susceptibility of different tissues.
The anemic picture is usually the first to appear in most patients. The reduced production of functional red blood cells leads to generally macrocytic anemia, but in more advanced cases, pancytopenia may occur, involving both the leukocyte and platelet lines. The classic symptoms of anemia include:
The presence of mild jaundice may accompany more severe cases, a sign of intramedullary hemolysis secondary to ineffective erythropoiesis.
Neurological alterations are a distinctive and serious aspect of vitamin B12 deficiency, which may arise even in the absence of overt anemia. Impaired methylation and the accumulation of methylmalonyl-CoA damage myelin, leading to a subacute combined degeneration of the posterior and lateral spinal tracts. Clinically, the following can be observed:
It is important to highlight that, unlike most other anemias, neurological alterations may be irreversible if treatment is not initiated promptly.
Involvement of the digestive tract, although less specific, represents an additional clinical clue. Patients may report:
These manifestations, if considered in isolation, may go unnoticed; however, their simultaneous presence with hematological or neurological alterations should immediately raise suspicion of a vitamin B12 deficiency.
The diagnosis of anemia due to vitamin B12 deficiency requires a systematic approach that integrates clinical, laboratory, and, when necessary, instrumental data. Timely recognition of the deficiency is crucial to prevent irreversible neurological complications that can arise even in the absence of overt anemia.
Diagnostic suspicion arises from the combined observation of hematological, neurological, and gastrointestinal manifestations, especially in patients with known risk factors such as a vegan diet, gastrointestinal diseases, or advanced age. The presence of unexplained macrocytic anemia, associated with neurological signs like paresthesias or sensory ataxia, should immediately direct attention to a possible vitamin B12 deficiency.
The first step in the diagnostic pathway is the execution of a complete blood count. Anemia typically presents as macrocytic, with a mean corpuscular volume (MCV) greater than 100 fL. In more advanced cases, pancytopenia can also be observed, reflecting the involvement of the leukocyte and platelet lines, secondary to ineffective erythropoiesis.
The peripheral blood smear reveals characteristic alterations: the presence of megalocytes, large and irregularly shaped red blood cells, and hypersegmented neutrophils, with nuclei divided into more than five lobes. These findings reflect the disorganization of cell division caused by impaired DNA synthesis in hematopoietic precursors.
The measurement of serum vitamin B12 is the cornerstone of biochemical diagnosis. Values below 200 pg/mL confirm the deficiency, while values between 200 and 300 pg/mL require further assessment through the measurement of homocysteine and methylmalonic acid levels. Both are elevated in B12 deficiency: homocysteine due to impaired methylation, and methylmalonic acid due to disrupted myelin synthesis.
Additional signs of ineffective erythropoiesis include increased lactate dehydrogenase (LDH) and indirect bilirubin levels, indirect markers of intramedullary hemolysis secondary to premature erythroid precursor death.
Once the deficiency is confirmed, it is essential to identify the underlying cause. In suspected cases of pernicious anemia, anti-intrinsic factor and anti-parietal cell antibodies are searched for, as they are highly specific. An upper gastrointestinal endoscopy with biopsy can document the presence of atrophic gastritis, typical of pernicious anemia or other predisposing conditions.
In patients with a history of intestinal resections, chronic inflammatory bowel diseases, or bariatric surgery, the etiological orientation is more straightforward, related to anatomical or functional alterations of the gastrointestinal tract.
In rare cases, diagnosis can be supported by a therapeutic test: a rapid hematological response to vitamin B12 administration functionally confirms the deficiency.
In the presence of significant neurological symptoms, magnetic resonance imaging (MRI) can document white matter alterations of the spinal cord and brain compatible with subacute combined degeneration. However, imaging is not routinely performed and is reserved for complex cases or when extensive neurological damage is suspected.
The diagnostic pathway must follow a clear progression:
Only through this integrated evaluation can a timely diagnosis be achieved, allowing appropriate therapy to be initiated and the progression of complications prevented.
The treatment of anemia due to vitamin B12 deficiency aims primarily at the rapid correction of the vitamin deficit, the recovery of compromised hematological and neurological functions, and the prevention of relapses. Therapeutic intervention must be timely, as neurological damage caused by prolonged deficiency can become irreversible.
The choice of the administration route depends on the etiology and the severity of the deficiency. In patients with intestinal absorption disorders, such as pernicious anemia or ileal resections, parenteral administration is necessary, whereas in cases of isolated dietary deficiencies, oral supplementation may be sufficient.
In more severe cases, the protocol provides an intensive approach:
When feasible, high-dose oral therapy (1000–2000 mcg/day) is a valid alternative, exploiting the passive intestinal absorption mechanism that is independent of intrinsic factor.
The response to treatment is generally rapid. Within a few days, a reticulocyte crisis can be observed, indicating the recovery of effective erythropoiesis. Hemoglobin begins to rise by approximately 1–2 g/dL per week, with complete normalization within 6–8 weeks. The mean corpuscular volume (MCV) normalizes more slowly, reflecting the time required for the replacement of red blood cells.
From a neurological standpoint, symptoms may improve within weeks or months, but complete reversibility depends on the duration of the deficiency: the earlier the intervention, the greater the functional recovery.
In parallel with vitamin supplementation, it is essential to address the primary cause:
The prognosis of anemia due to vitamin B12 deficiency is excellent if the diagnosis is made early and treatment is promptly initiated. Hematological parameters usually normalize within 2 months, with full recovery of erythropoietic function.
However, neurological complications, if present for a prolonged period before treatment, may not be completely reversible. Deep sensory disturbances, ataxia, and cognitive impairments may persist to varying degrees, even after vitamin levels are restored.
The main complications associated with untreated vitamin B12 deficiency include:
Long-term follow-up is essential, especially in patients with chronic deficiency, to monitor the adequacy of supplementation, prevent relapses, and enable early identification of potential neoplastic or neurological complications.
Early diagnosis and appropriate treatment can radically alter the natural course of the disease, preventing permanent damage and significantly improving the patient's quality of life.